Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Lionheart Acquisition Co. II (LCAP) Competitors

Lionheart Acquisition Co. II logo

LCAP vs. PACS, ARDT, SEM, QDEL, AGIO, CERT, PGNY, LMAT, BCRX, and GRAL

Should you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include PACS Group (PACS), Ardent Health (ARDT), Select Medical (SEM), QuidelOrtho (QDEL), Agios Pharmaceuticals (AGIO), Certara (CERT), Progyny (PGNY), LeMaitre Vascular (LMAT), BioCryst Pharmaceuticals (BCRX), and GRAIL (GRAL). These companies are all part of the "medical" sector.

Lionheart Acquisition Co. II vs. Its Competitors

PACS Group (NYSE:PACS) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

PACS Group's return on equity of 0.00% beat Lionheart Acquisition Co. II's return on equity.

Company Net Margins Return on Equity Return on Assets
PACS GroupN/A N/A N/A
Lionheart Acquisition Co. II N/A -44.30%1.39%

In the previous week, PACS Group had 3 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 3 mentions for PACS Group and 0 mentions for Lionheart Acquisition Co. II. Lionheart Acquisition Co. II's average media sentiment score of 0.00 beat PACS Group's score of -0.11 indicating that Lionheart Acquisition Co. II is being referred to more favorably in the news media.

Company Overall Sentiment
PACS Group Neutral
Lionheart Acquisition Co. II Neutral

PACS Group has higher revenue and earnings than Lionheart Acquisition Co. II.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PACS Group$3.11B0.63$112.87MN/AN/A
Lionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A

PACS Group currently has a consensus target price of $34.29, suggesting a potential upside of 164.75%. Given PACS Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe PACS Group is more favorable than Lionheart Acquisition Co. II.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PACS Group
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Lionheart Acquisition Co. II
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PACS Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.

Summary

PACS Group beats Lionheart Acquisition Co. II on 8 of the 10 factors compared between the two stocks.

Get Lionheart Acquisition Co. II News Delivered to You Automatically

Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LCAP vs. The Competition

MetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ Exchange
Market Cap$494.56M$151.95M$5.50B$8.94B
Dividend YieldN/AN/A5.25%4.04%
P/E RatioN/A0.5926.9720.11
Price / SalesN/A22.77426.02119.76
Price / Cash20.6411.7036.8257.86
Price / Book-9.403.407.985.56
Net Income$3.21M$1.30M$3.16B$248.40M

Lionheart Acquisition Co. II Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LCAP
Lionheart Acquisition Co. II
N/A$26.80
-0.3%
N/A+6,644.8%$494.56MN/A0.003
PACS
PACS Group
2.8771 of 5 stars
$12.93
+0.1%
$34.29
+165.2%
-57.0%$1.97B$3.11B0.0032,433News Coverage
ARDT
Ardent Health
3.5084 of 5 stars
$13.74
+0.6%
$20.67
+50.4%
N/A$1.95B$5.97B8.4324,900
SEM
Select Medical
5 of 5 stars
$15.23
+0.3%
$26.00
+70.8%
-58.6%$1.95B$5.19B11.3644,100Positive News
QDEL
QuidelOrtho
4.432 of 5 stars
$29.79
+3.4%
$44.33
+48.8%
+1.5%$1.95B$2.78B-5.996,600
AGIO
Agios Pharmaceuticals
4.0693 of 5 stars
$34.37
+3.3%
$58.60
+70.5%
-11.9%$1.93B$36.50M3.06390
CERT
Certara
4.7126 of 5 stars
$11.52
-1.5%
$15.67
+36.0%
-20.3%$1.90B$385.15M-576.001,546
PGNY
Progyny
1.3841 of 5 stars
$22.06
+0.3%
$23.45
+6.3%
-14.1%$1.89B$1.17B38.70310News Coverage
Analyst Upgrade
LMAT
LeMaitre Vascular
1.901 of 5 stars
$83.69
+0.8%
$97.83
+16.9%
+1.3%$1.88B$219.86M42.27490
BCRX
BioCryst Pharmaceuticals
4.4608 of 5 stars
$9.00
+0.4%
$16.70
+85.6%
+36.9%$1.87B$450.71M-34.62530
GRAL
GRAIL
0.5685 of 5 stars
$49.23
-4.3%
$31.50
-36.0%
N/A$1.85B$125.60M0.001,360Positive News

Related Companies and Tools


This page (NASDAQ:LCAP) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners